Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression

Chongqing Medical University

Status: Completed

Conditions: Major Depressive Disorder; Psychiatric Disorder; Metabolic Disorder

Treatments: Diagnostic Test: 17-HAMD

Study type: Observational

Funder types: Other

Identifiers

NCT06331572

1stChongqingMU-TRD

Details and patient eligibility

About

This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.

Enrollment: 162 patients

Sex: All

Ages: 12 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

FEDN-MDD：

1. Age 12-18 years
2. Meet the diagnostic criteria for MDD according to the DSM-5
3. First-episode and drug-naive
4. HAMD-17 score > 17

TRD:

1. Age 12-18 years
2. Meet the diagnostic criteria for MDD according to the DSM-5
3. HAMD-17 score > 13
4. Currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms <50%)

HC:

1. age 12-18 years
2. HAMD-17 score < 7
3. HCs without a personal history of a mental illness or family history in a first-degree relative

Exclusion criteria

FEDN-MDD、TRD：

1. the presence or past history of severe medical, neurological or psychiatric disorders (other than MDD in patients)
2. anxiety comorbidity was not considered an exclusion criterion provided that MDD was the main diagnosis and the primary reason for seeking assistance
3. substance abuse, head trauma, or loss of consciousness
4. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
5. Pregnant and lactating women

HC:

1. the presence or past history of severe medical, neurological or psychiatric disorders
2. substance abuse, head trauma, or loss of consciousness
3. Chronic physical diseases that significantly affect peripheral metabolism or neurological function
4. Pregnant and lactating women

Trial design

162 participants in 3 patient groups

TRD

Description:

1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 3. HAMD-17 score \> 13 4. currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%)

Treatment:

Diagnostic Test: 17-HAMD

FEDN-MDD

Description:

1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 2. First-episode and drug-naive 4. HAMD-17 score \> 17

Treatment:

Diagnostic Test: 17-HAMD

HC

Description:

1. age 12-18 years 2. HAMD-17 score \< 7 3. HCs without a personal history of a mental illness or family history in a first-degree relative

Treatment:

Diagnostic Test: 17-HAMD